SignaCor
Biotechnology Research
Belfast, United Kingdom
3 employees
- Employees
- 3
- Contacts
- 2
- Emails
- 2
SignaCor Overview
- Headquarters
- Belfast, United Kingdom
- Website
- www.signacor.co.uk
- Industry
- Biotechnology Research
- Employees
- 3
- Founded
- 2024
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
Keywords
About SignaCor
SignaCor is a clinical stage, drug development company, spun-out from Queen’s University Belfast, dedicated to the treatment of cardiac disease. At SignaCor, we are pioneering a first-in-class therapeutic approach to symptomatic hypertrophic cardiomyopathy (HCM)—one that goes beyond symptom management to target the underlying disease pathology. Cardiaza is the first and only treatment that harnesses DNA methylation to address multiple underlying causes of symptomatic HCM, including established fibrosis, a key driver of disease progression. Ph2a Clinical Trial commencing in 2025.
SignaCor Contact Details
- People in AeroLeads
- 2
- With contact data
- 2
- Email contacts
- 2
- 100.0% coverage
SignaCor Org Chart
Sample employees and titles| Name | Title | Location | Contact |
|---|---|---|---|
| Chris Watson | Lecturer & Principal Investigator | Belfast Metropolitan Area, United Kingdom |
Email
|
| John Fox | Non-executive Director, Start-ups/sme | Bath, England, United Kingdom |
Email
|
Compare Similar Companies to SignaCor
Digital Science
Software Development
Health Data Research UK (HDR UK)
Research Services
SciLeads
It Services And It Consulting
Invest Northern Ireland – Americas
International Trade And Development
AilseBio
Biotechnology Research
KlasTherapeutics
Health And Human Services
KinoPharma
Multi-signal peer
APT Therapeutics
Medical Equipment Manufacturing
Anonox GmbH
Executive Offices
TheraDuty
Hospitals And Health Care